GlassScriptPhysician profile
Todd D Severin
NPI 1144225343
$87,512.90
in general payments reported to CMS, 2019-2025
28 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $1,605 · 2021: $3,800 · 2022: $7,060 · 2023: $3,153 · 2024: $1,073 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Consulting Fee: $2,000 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.38 |
| Consulting Fee | $2,000.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $58,923.89 | 2019-2024 | Cirrus Hd-Oct, Humphrey Hfa, Clarus |
| Aerie Pharmaceuticals, INC. | $10,546.04 | 2019-2021 | |
| Alcon Vision LLC | $6,873.68 | 2021-2025 | Rocklatan, Voyager Dslt, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $5,236.66 | 2019-2021 | |
| Abbvie INC. | $1,355.47 | 2022-2025 | Durysta, Lumigan, Xen Glaucoma Treatment System |
| Johnson & Johnson Surgical Vision, INC. | $1,158.97 | 2019-2022 | |
| Allergan, INC. | $732.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $425.32 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $395.77 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $356.68 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $331.33 | 2022-2025 | Miebo, Alrex, Lotemax Sm |
| Biotissue Holdings INC. | $230.28 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $145.97 | 2019-2020 | |
| Thea Pharma INC. | $138.05 | 2022-2025 | Iyuzeh |
| Sight Sciences, INC. | $137.21 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $93.75 | 2024-2025 | Iheezo, Vevye |
| Mallinckrodt Hospital Products INC. | $74.02 | 2025 | Acthar |
| Kala Pharmaceuticals, INC. | $66.71 | 2019-2022 | |
| Iridex Corporation | $64.83 | 2019-2021 | |
| Glaukos Corporation | $38.63 | 2025 | Epioxa |
| Rxsight INC | $38.31 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Dompe US, INC. | $29.54 | 2025 | Oxervate |
| Amgen INC. | $28.11 | 2025 | Tepezza |
| Beaver-Visitec International, INC. | $24.85 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.91 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $17.07 | 2024 | Xdemvy |
| New World Medical,INC. | $13.85 | 2022 | |
| Rayner Intraocular Lenses Limited | $13.61 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Severin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.